(Q39933788)

English

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

scientific article published on 8 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

U A Matulonis

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

R T Penson

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

S M Domchek

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

B Kaufman

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

R Shapira-Frommer

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

M W Audeh

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

S Kaye

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

L R Molife

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

K A Gelmon

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J D Robertson

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H Mann

11

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

T W Ho

12

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

R L Coleman

13

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

8 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1013-1019

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Maintenance therapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Platinum neurotoxicity pharmacogenetics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW133

21 January 2018

Identifiers

10.1093/ANNONC/MDW133

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

release_bd3xjwqctncvvh55ksjikmfffe

1 reference

https://api.fatcat.wiki/v0/release/bd3xjwqctncvvh55ksjikmfffe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39933788&oldid=1879051436"